Pasithea stock soars as high as 190% on preclinical data

seekingalpha2023-12-12

Pasithea Therapeutics (NASDAQ:KTTA) shares soared as high as 190% in morning trading Monday after the company released encouraging data from two preclinical studies of its drug candidate PAS-004. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2390363094?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170151024/image_1170151024.jpg","is_english":true,"pubTime":"2023-12-12 00:15","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2390363094","market":"us","top_or_hot":-1,"title":"Pasithea stock soars as high as 190% on preclinical data","media":"seekingalpha","content":"<div>\n<p>Pasithea Therapeutics (NASDAQ:KTTA) shares soared as high as 190% in morning trading Monday after the company released encouraging data from two preclinical studies of its drug candidate PAS-004. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4045130-pasithea-stock-soars-on-preclinical-data\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pasithea stock soars as high as 190% on preclinical data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPasithea stock soars as high as 190% on preclinical data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-12 00:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4045130-pasithea-stock-soars-on-preclinical-data><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pasithea Therapeutics (NASDAQ:KTTA) shares soared as high as 190% in morning trading Monday after the company released encouraging data from two preclinical studies of its drug candidate PAS-004. ...</p>\n\n<a href=\"https://seekingalpha.com/news/4045130-pasithea-stock-soars-on-preclinical-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4045130-pasithea-stock-soars-on-preclinical-data","article_id":"2390363094","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170151024/image_1170151024.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2390363094","pubTimestamp":1702311305,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Pasithea Therapeutics  shares soared as high as 190% in morning trading Monday after the company released encouraging data from two preclinical studies of its drug candidate PAS-004. Shares of Pasithea recently sold for $0.69 at 11:00 a.m. ET, up 130% from Friday's close, after hitting an earlier high of $0.87. The biotech company has been evaluating PAS-400's anti-tumor efficacy in NRAS mutation cancer xenograft models.  Pasithea said that in one study, PAS-004 exhibited superior anti-tumor efficacy to binimetinib and selumetinib when taken at equivalent doses for lung cancer. In another study, PAS-004 exhibited superior anti-tumor efficacy to selumetinib and similar efficacy to binimetinib when taken in equivalent doses for liver cancer.  The biotech company hopes to begin Phase 1 testing for the product as early as Q1, pending acceptance of its Investigational New Drug application by the FDA.  More on Pasithea Therapeutics  Pasithea stock jumps 12% on update for anti-tumor drug PAS-","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KTTA":"Pasithea Therapeutics Corp."},"translate_title":"根据临床前数据，帕西忒亚股票飙升至190%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KTTA":1},"content_text":"Pasithea Therapeutics (NASDAQ:KTTA) shares soared as high as 190% in morning trading Monday after the company released encouraging data from two preclinical studies of its drug candidate PAS-004. Shares of Pasithea recently sold for $0.69 at 11:00 a.m. ET, up 130% from Friday's close, after hitting an earlier high of $0.87. The biotech company has been evaluating PAS-400's anti-tumor efficacy in NRAS mutation cancer xenograft models.  Pasithea said that in one study, PAS-004 exhibited superior anti-tumor efficacy to binimetinib and selumetinib when taken at equivalent doses for lung cancer. In another study, PAS-004 exhibited superior anti-tumor efficacy to selumetinib and similar efficacy to binimetinib when taken in equivalent doses for liver cancer.  The biotech company hopes to begin Phase 1 testing for the product as early as Q1, pending acceptance of its Investigational New Drug application by the FDA.  More on Pasithea Therapeutics  Pasithea stock jumps 12% on update for anti-tumor drug PAS-004 Financial information for Pasithea Therapeutics","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2390363094"}